PE20090246A1 - Preparacion farmaceutica acuosa - Google Patents

Preparacion farmaceutica acuosa

Info

Publication number
PE20090246A1
PE20090246A1 PE2008000805A PE2008000805A PE20090246A1 PE 20090246 A1 PE20090246 A1 PE 20090246A1 PE 2008000805 A PE2008000805 A PE 2008000805A PE 2008000805 A PE2008000805 A PE 2008000805A PE 20090246 A1 PE20090246 A1 PE 20090246A1
Authority
PE
Peru
Prior art keywords
aqueous pharmaceutical
preparation
pharmaceutical preparation
glycerin
refers
Prior art date
Application number
PE2008000805A
Other languages
English (en)
Inventor
Holger Bauer
Norbert Rasenack
Kerstin Ammer
Bianka Kemmerer
Kirstin Heil
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PE20090246A1 publication Critical patent/PE20090246A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ACUOSA, QUE COMPRENDE: a) 1-(2-DIMETILAMINO-ETIL)-3-((2R,4aS,5R,10bS)-5-FENIL-9-TRIFLUOROMETIL-3,4,4a,5,6,10b-HEXAHIDRO-2H-PIRANO[3,2-c]QUINOLIN-2-ILMETIL)-UREA COMO PRINCIPIO ACTIVO; b)UN TENSIOACTIVO NO IONICO, EL CUAL TIENE UN HLB > 8, TAL COMO RICINOLEATO DE GLICERINA-POLIETILENGLICOL, MONOESTERATO DE POLIOXIETILEN(20)-SORBITANO, ENTRE OTROS; c)UN SOLVENTE ORGANICO QUE CONTIENE POR LO MENOS UN GRUPO HIDROXILO, TAL COMO ETANOL, PROPILENGLICOL, GLICERINA, GLUCOFUROL Y/O POLIETILENGLICOLES. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION Y UN KIT CONTENIENDO LA PREPARACION Y UN RECIPIENTE CON AGUA APROPIADA PARA PRODUCIR LA PREPARACION FARMACEUTICA ACUOSA
PE2008000805A 2007-05-10 2008-05-08 Preparacion farmaceutica acuosa PE20090246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007021862A DE102007021862A1 (de) 2007-05-10 2007-05-10 Wässrige pharmazeutische Zubereitung

Publications (1)

Publication Number Publication Date
PE20090246A1 true PE20090246A1 (es) 2009-03-19

Family

ID=39537491

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000805A PE20090246A1 (es) 2007-05-10 2008-05-08 Preparacion farmaceutica acuosa

Country Status (20)

Country Link
US (1) US20100210681A1 (es)
EP (1) EP2142169B1 (es)
JP (1) JP2010526783A (es)
KR (1) KR20100029758A (es)
CN (1) CN101677941A (es)
AR (1) AR066504A1 (es)
AT (1) ATE530164T1 (es)
AU (1) AU2008250717A1 (es)
BR (1) BRPI0811431A2 (es)
CA (1) CA2686765A1 (es)
CL (1) CL2008001384A1 (es)
CO (1) CO6220901A2 (es)
DE (1) DE102007021862A1 (es)
EA (1) EA200901498A1 (es)
EC (1) ECSP099788A (es)
IL (1) IL201912A0 (es)
MX (1) MX2009012035A (es)
PE (1) PE20090246A1 (es)
TW (1) TW200911252A (es)
WO (1) WO2008138459A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
KR102126727B1 (ko) 2018-03-29 2020-07-07 이혜영 자동차 표면 광택방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE507220T1 (de) * 2003-12-20 2011-05-15 Merck Patent Gmbh Tetrahydropyranochinolinderivate
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
NZ574236A (en) * 2006-06-19 2010-11-26 Merck Patent Gmbh Processes for preparing pyranoquinolines and crystal forms thereof

Also Published As

Publication number Publication date
AR066504A1 (es) 2009-08-26
CL2008001384A1 (es) 2009-09-25
IL201912A0 (en) 2010-06-16
DE102007021862A1 (de) 2008-11-13
CO6220901A2 (es) 2010-11-19
ECSP099788A (es) 2010-01-29
AU2008250717A1 (en) 2008-11-20
ATE530164T1 (de) 2011-11-15
US20100210681A1 (en) 2010-08-19
WO2008138459A2 (de) 2008-11-20
KR20100029758A (ko) 2010-03-17
JP2010526783A (ja) 2010-08-05
EP2142169A2 (de) 2010-01-13
BRPI0811431A2 (pt) 2015-06-16
EP2142169B1 (de) 2011-10-26
CA2686765A1 (en) 2008-11-20
TW200911252A (en) 2009-03-16
WO2008138459A3 (de) 2009-06-04
MX2009012035A (es) 2009-11-18
EA200901498A1 (ru) 2010-04-30
CN101677941A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
AR075284A1 (es) Formulaciones fitosanitarias liquidas acuosas
CL2012001310A1 (es) Composicion que comprende un oligopeptido ciclo-(arg-gly-asp-dphe-nmeval) que tiene una solubilidad en agua a 20ºc de entre 1 mg/ml y 20 mg/ml y con uno o varios compuestos lipofilicos y/o anfifílicos; proceso para preparar dicha composicion.
MY158687A (en) Micro-needle device and preparation method
GT200000219A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
CR20140539A (es) Preparación que contiene por lo menos un fungicida conazólico
ES2421613T3 (es) Composición farmacéutica externa
CL2011001853A1 (es) Uso de una combinacion farmaceutica que comprende linagliptina y un segundo agente antidiabetico seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, entre otros, y, opcionalmente, un tercer agente antidiabetico, para tratar diabetes mellitus tipo 2 y complicaciones de la diabetes, entre otras.
CL2009000625A1 (es) Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo.
AR053737A1 (es) Formulacion pediatrica de topiramato
CO6390097A2 (es) Formulaciones para el cuidado oral que incrementa la cantidad de zinc soluble
CL2008000411A1 (es) Composicion farmaceutica que comprende un primer compuesto que incrementa el ph del estomago, un segundo agente que reduce el ph y al menos un tercer agente seleccionado entre una vitamina, un mineral y otro farmaco; y su uso para mejorar la absorcio
PE20130826A1 (es) Trampa para mosquitos
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
PE20090605A1 (es) Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma
AR059357A1 (es) Formulaciones farmaceuticas
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
CL2008001605A1 (es) Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia.
AR051385A1 (es) Agentes de curtido a base de isocianato
PE20210413A1 (es) Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad
CO6382164A2 (es) Solucion acuosa para la preservacion de tejidos y organos
AR049697A1 (es) Sistema para generar una forma de dosificacion bioactiva y metodo para hacer una forma de dosificacion farmaceutica
PE20090246A1 (es) Preparacion farmaceutica acuosa
AR054729A1 (es) Sistema de administracion
AR043786A1 (es) Dispositivo dispensador de substancia hidrofila

Legal Events

Date Code Title Description
FC Refusal